Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice

Hypertension

Volumn 54, Issue 3, 2009, Pages 633-638

  Yamamoto, Eiichiro ^a   Kataoka, Keiichiro ^a   Dong, Yi Fei ^a   Nakamura, Taishi ^a   Fukuda, Masaya ^a   Tokutomi, Yoshiko ^a   Matsuba, Shinji ^a   Nako, Hisato ^a   Nakagata, Naomi ^b   Kaneko, Takehito ^a   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Combination therapy; eNOS; Inflammation; Oxidative stress; Synergistic effect

Indexed keywords

ALBUMIN; ALISKIREN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; VALSARTAN; AMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG DERIVATIVE; FUMARIC ACID DERIVATIVE; MESSENGER RNA; NOS3 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; SUPEROXIDE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDITIS; CONTROLLED STUDY; DRUG EFFICACY; FEMORAL ARTERY; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; KIDNEY INJURY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ROTATOR CUFF INJURY; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; ANIMAL; BLOOD; BLOOD PRESSURE; C57BL MOUSE; CARDIOMEGALY; CARDIOVASCULAR SYSTEM; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; INJURY; INTIMA; KIDNEY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY;

AMIDES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUMARATES; GENE EXPRESSION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RNA, MESSENGER; SUPEROXIDES; TETRAZOLES; TUNICA INTIMA; VALINE;

EID: 70349251477     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.133884     Document Type: Article

References (28)

1. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52: 11-34.
2. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
3. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1-8.
4. Brown MJ. Aliskiren. Circulation. 2008;118:773-784.
5. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008;7:399-410.
6. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Pat. 2003;13:589-603.
7. Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, Hatanaka M, Fujiki T, Maeda H, Takahashi S, Takeshita A. Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest. 2003;112:1871-1879.
8. Sawa T, Zaki MH, Okamoto T, Akuta T, Tokutomi Y, Kim-Mitsuyama S, Ihara H, Kobayashi A, Yamamoto M, Fujii S, Arimoto H, Akaike T. Protein S-guanylation by the biological signal 8-nitroguanosine 3,5- cyclic monophosphate. Nat Chem Biol. 2007;3:727-735.
9. Izumi Y, Kim S, Yoshiyama M, Izumiya Y, Yoshida K, Matsuzawa A, Koyama H, Nishizawa Y, Ichijo H, Yoshikawa J, Iwao H. Activation of apoptosis signal-regulating kinase 1 in injured artery and its critical role in neointimal hyperplasia. Circulation. 2003;108:2812-2818.
10. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia- induced atherosclerosis in mice. J Clin Invest. 2008;118:984-993.
11. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
12. Gamboa A, Shibao C, Diedrich A, Choi L, Pohar B, Jordan J, Paranjape S, Farley G, Biaggioni I. Contribution of endothelial nitric oxide to blood pressure in humans. Hypertension. 2007;49:170-177. (Pubitemid 46360357)
13. Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111:310-314.
14. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363-368.
15. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation. 1996;94:1298-1303.
16. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension. 1998;32:3-8.
17. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-229.
18. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
19. McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
20. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52: 563-572.
21. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115:500-508.
22. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
23. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol. 2005;25: 274-278.
24. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-248.
25. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
26. Yamamoto E, Dong YF, Kataoka K, Yamashita T, Tokutomi Y, Matsuba S, Ichijo H, Ogawa H, Kim-Mitsuyama S. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension. 2008; 52:573-580.
27. Yamamoto E, Kataoka K, Shintaku H, Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure. Arterioscler Thromb Vasc Biol. 2007;27:2569-2575.
28. Yamamoto E, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Lai ZF, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol. 2007; 27:556-563.